Noninsulin Medications for Type 2 Diabetes

Comparative drug-class overview

Class / examples	Primary mechanism	Major prescribing considerations
Biguanide • metformin	Reduces hepatic glucose production and improves peripheral insulin sensitivity	GI intolerance; renal function; dehydration/acute illness risk; B12 concern.
Sulfonylureas • glipizide, glimepiride, glyburide	Promote pancreatic insulin secretion	Hypoglycemia, weight gain, meal regularity, older age, kidney function.
Meglitinides • repaglinide, nateglinide	Short-acting meal-related insulin secretion	Timing with meals; withhold when meal is skipped; drug interactions.
TZDs • pioglitazone, rosiglitazone	Improve insulin sensitivity	Fluid retention, heart failure, weight gain, liver-related considerations.
Alpha-glucosidase inhibitors • acarbose, miglitol	Delay intestinal carbohydrate digestion/absorption	Take with first bite; GI symptoms; bowel disease exclusions.
DPP-4 inhibitors • sitagliptin, saxagliptin, linagliptin	Prolong endogenous incretin activity	Weight neutral; renal adjustment varies (none for linagliptin); saxagliptin and alogliptin carry heart failure precautions.
GLP-1 receptor agonists • exenatide and others	Glucose-dependent insulin release, glucagon modulation, slowed gastric emptying, satiety	GI tolerability, product-specific timing and warnings, route/frequency.
SGLT2 inhibitors • canagliflozin, dapagliflozin	Block renal glucose reabsorption	Genital infections, volume status, acute illness interruption, kidney/HF-related indications.
Niche agents • pramlintide, quick-release bromocriptine, colesevelam	Amylin replacement, central dopamine agonism, or intestinal bile acid binding	Limited roles; pramlintide/insulin hypoglycemia, bromocriptine orthostasis, colesevelam drug-binding interactions.

Relative efficacy is not the same as clinical value

Comparative studies report approximate A1c reductions as ranges, not guarantees. Metformin and sulfonylureas are described as high-efficacy agents (often about 1.5–2 percentage points in appropriate populations); DPP-4 inhibitors generally provide a smaller reduction (about 0.5–0.9 points); SGLT2 inhibitors about 0.5–1 point; GLP-1 receptor agonists about 0.8–1.5 points; and dual GIP/GLP-1 agonism can produce larger reductions in selected trials. Baseline A1c, adherence, dose, background therapy, and trial population affect observed benefit (Sease & Blake, 2026).

Comparing only A1c reduction can therefore mislead. A drug that modestly reduces A1c but lowers heart failure hospitalization or kidney disease progression may be preferable to one with greater glucose reduction and no comparable organ benefit. Conversely, a patient experiencing symptomatic hypoglycemia requires deintensification even if the laboratory result appears favorable.

Mechanism determines the safety question

Distinguish glucose-independent insulin secretion with sulfonylureas and meglitinides from therapies that do not directly force pancreatic insulin release. Secretagogues warrant particularly careful assessment of missed meals and hypoglycemia. Metformin primarily addresses hepatic glucose production; TZDs address insulin resistance but raise fluid-retention concerns. Incretin-based agents and renal glucose-excretion drugs change glucose regulation through different mechanisms, so similar A1c responses do not imply interchangeable safety or organ outcomes.

Metformin

Metformin is an oral biguanide that reduces hepatic glucose output, improves peripheral insulin sensitivity, and does not directly stimulate beta-cell insulin secretion. It is generally not a cause of hypoglycemia when used alone. Immediate-release and extended-release formulations differ in administration and GI tolerability; intolerance can become an early obstacle to adherence.

Before use, assess renal function, relevant acute or chronic illness, intake and hydration, alcohol exposure, gastrointestinal tolerance, and medication access. Consider whether persistent symptoms reflect dose escalation, timing, or formulation rather than assuming pharmacologic treatment failure. Long-term therapy warrants attention to possible vitamin B12 deficiency.

Prescribing, renal assessment, and intolerance

Metformin reduces hepatic glucose production and does not directly stimulate insulin secretion. A common immediate-release initiation is 500 mg with an evening meal or 500 mg twice daily, followed by gradual titration as tolerated; extended-release formulations may improve gastrointestinal tolerability. Discuss expected nausea or loose stools, strategies for taking the medication consistently with food, and reasons to seek assessment for persistent severe gastrointestinal symptoms or dehydration (Sease & Blake, 2026).

Long-term metformin exposure can reduce vitamin B12 levels. Include neuropathy, anemia, cognitive symptoms, and dietary risk when evaluating the need for B12 assessment; a patient with worsening neuropathy does not necessarily have diabetes progression alone (Sease & Blake, 2026).

Initiation, tolerance, and persistence

For an adult with stable kidney function, a low starting dose taken with food and gradual titration can improve tolerability. Before escalating, establish the renal-function category: metformin is contraindicated with eGFR below 30 mL/min/1.73 m²; initiation at eGFR 30–44 mL/min/1.73 m² is generally avoided, while continuation in a patient already receiving it requires reassessment, lower dosing when indicated, and closer renal surveillance. The immediate-release and extended-release products have different limits and administration instructions. Address acute dehydration, hypoxemia, or evolving AKI separately from stable CKD, and reconcile the actual product before issuing instructions for iodinated contrast (Sease & Blake, 2026, Chapter 44, Table 44–8).

Clinical decision: metformin during acute illness

A patient taking metformin develops gastroenteritis, poor oral intake, orthostasis, and rising creatinine. The immediate question is whether continued renal elimination is reliable during this acute illness, even if the prior eGFR supported chronic metformin therapy. Assess dehydration and possible AKI, discuss temporary interruption within the individualized sick-day plan, and determine what laboratory or clinical recovery will permit resumption. Do not automatically treat a stable CKD diagnosis as equivalent to acute hypoperfusion (Sease & Blake, 2026).

Sulfonylureas and meglitinides

Sulfonylureas increase insulin release, so hypoglycemia and weight gain may offset their low acquisition cost. Glipizide, glyburide, and glimepiride are examples, but they should not be treated as equally suitable in older adults or people with reduced kidney function. Assess food security, eating schedule, awareness of low glucose, prior falls or assistance needs, and drug interactions before prescribing.

Meglitinides address meal-associated glucose excursions through short-acting insulin secretion. Repaglinide and nateglinide must be coordinated with actual meals; omit a scheduled meal-linked dose when that meal is skipped. Repaglinide is contraindicated with gemfibrozil. Avoid concomitant clopidogrel when possible; if it cannot be avoided, the repaglinide label requires a 0.5 mg starting dose before meals and a maximum total of 4 mg/day. The repaglinide label also advises against combination with NPH insulin because of serious cardiovascular adverse reactions. Review the exact product and interacting drugs before prescribing (Repaglinide tablets, 2025).

Selecting and safely retiring secretagogues

Glipizide, glimepiride, and glyburide close ATP-sensitive potassium channels in pancreatic beta cells, promoting insulin secretion even when glucose or intake is low. Repaglinide and nateglinide also stimulate insulin secretion but have shorter meal-associated action. Because all require functioning beta cells, they are inappropriate substitutes for insulin in absolute insulin deficiency.

A patient with irregular meals, falls, reduced renal function, or prior severe hypoglycemia often has an unfavorable benefit-harm balance with a secretagogue. Glyburide is particularly problematic when hypoglycemia can be prolonged. If a GLP-1 receptor agonist or insulin regimen is intensified, reassess concomitant sulfonylurea dosing rather than simply stacking therapies. Patients must know what to do when a planned meal is skipped; meal-linked medications should not be taken mechanically without food.

An apparent treatment “failure” should trigger medication reconciliation, access review, adherence assessment, and evaluation of progressive beta-cell dysfunction. Increasing a secretagogue after multiple hypoglycemic episodes may deepen risk without solving the true reason for an elevated A1c.

Secretagogues should not be layered to overcome a high A1c. In a patient with recurrent lows on glyburide, the immediate decision is to assess and usually reduce or discontinue the hypoglycemia-producing agent; switching to repaglinide does not eliminate risk. If a meal-related secretagogue remains appropriate, use a clearly documented meal-linked regimen and verify interactions and renal function (Sease & Blake, 2026).

Interaction review

Repaglinide is a meal-linked secretagogue. Current U.S. prescribing information recommends starting at 0.5 mg before each meal when baseline A1c is below 8%, or 1–2 mg before each meal when A1c is 8% or higher; a 0.5-mg starting dose is also recommended in severe renal impairment with CrCl 20–40 mL/min. Administer within 30 minutes before eating and omit the dose when a meal is skipped. Titrate no more frequently than weekly, with a maximum of 4 mg per meal or 16 mg/day. Concomitant gemfibrozil is contraindicated because of the risk of excessive repaglinide exposure and hypoglycemia. Do not combine a meglitinide with another insulin secretagogue. Check medication interactions, intake reliability, and hypoglycemia before considering use (Repaglinide tablets, 2025; Sease & Blake, 2026).

Thiazolidinediones

Pioglitazone and rosiglitazone increase responsiveness to insulin. They do not provide the immediate glucose correction seen with meal-time secretagogues. Their selection depends heavily on volume status, heart failure, edema, weight, liver assessment, and competing comorbidities. New dependent edema or worsening dyspnea after initiation should prompt reassessment of therapy rather than being interpreted merely as unrelated progression of diabetes.

Additional safety considerations for individual TZDs may include hepatic assessment, fracture risk and other agent-specific warnings. Contraindications and labeling should be checked for the particular drug.

Volume status, delayed effects, and contraindications

Pioglitazone improves peripheral insulin sensitivity through PPAR-gamma activation. Its full effect develops over weeks, so early escalation based on a few home readings can overstate failure. It generally does not cause hypoglycemia on its own, but combining it with insulin or secretagogues changes the risk profile.

Thiazolidinedione selection requires more than comparing A1c reductions. Weight gain, edema, fractures, and worsening heart failure may outweigh the benefit. Pioglitazone carries a boxed warning for causing or exacerbating heart failure; initiation is contraindicated in New York Heart Association (NYHA) class III or IV heart failure and is not recommended in symptomatic heart failure. After starting or increasing the dose, assess rapid weight gain, dyspnea, or edema; if heart failure develops, consider reducing or discontinuing pioglitazone while providing appropriate heart-failure care (Pioglitazone tablets, 2023).

Select the patient, not just the A1c

Pioglitazone and rosiglitazone improve tissue response to insulin. Dose initiation and escalation must be considered alongside the patient’s clinical profile: ask about edema, breathlessness, heart failure, liver disease, weight change, and fracture-related concerns. New peripheral edema after treatment initiation is not merely a cosmetic effect; assess whether the drug is causing clinically significant fluid retention.

Monitoring and reassessment

Document baseline cardiopulmonary symptoms and weight, then ask specifically about rapid weight gain, worsening ankle swelling, activity intolerance, and dyspnea. Review liver-related history and interacting drugs. If the patient develops new heart failure symptoms, reexamine the appropriateness of the class rather than assuming the glucose benefit justifies ongoing exposure.

Alpha-glucosidase inhibitors

Acarbose and miglitol reduce the postprandial rise in glucose by slowing intestinal carbohydrate digestion. The drugs are associated with flatulence, diarrhea, and abdominal discomfort, so the likely benefit must be weighed against gastrointestinal disease and tolerability. Administration with the first bite of a meal helps align action with carbohydrate intake.

Alpha-glucosidase inhibitors rarely cause hypoglycemia when used alone. When concomitant insulin or a secretagogue causes hypoglycemia, treat a conscious patient who can safely swallow with oral glucose (dextrose), not sucrose (table sugar), because acarbose delays sucrose digestion. Severe hypoglycemia requires appropriate emergency treatment, potentially glucagon or IV dextrose. Review the contributing insulin or secretagogue dose and confirm that the patient can demonstrate the rescue plan (Acarbose tablets, 2026).

Mealtime administration

Acarbose and miglitol affect carbohydrate digestion in the gastrointestinal tract and are aimed at postmeal glucose excursions. Administration is with the first bite of a meal; a 25 mg dose with meals is one example of a low initial dose, with gradual titration dependent on tolerance and the specific agent. Gas, abdominal discomfort, and diarrhea are predictable barriers to persistence; bowel disease or obstruction risk should be screened. Dose and escalation must follow the selected product’s prescribing information.

DPP-4 inhibitors

Agent-level renal differentiation

DPP-4 inhibitor doses must be selected by agent, not class. Sitagliptin is described at 100 mg once daily in the usual renal-function category, 50 mg once daily with intermediate renal impairment, and 25 mg once daily with severe impairment. Linagliptin is given as 5 mg once daily without routine renal dose adjustment; saxagliptin and alogliptin have their own reduced-dose categories. Verify the patient’s actual eGFR, product, indication, and current prescribing information before ordering or continuing treatment. None should be assumed to confer the established heart failure or kidney outcome benefit of an SGLT2 inhibitor merely because it also lowers A1c (Sease & Blake, 2026).

Renal prescribing requires agent-specific thresholds rather than a blanket DPP-4 class dose. The alogliptin label specifies 25 mg orally daily for CrCl at least 60 mL/min, 12.5 mg daily for CrCl 30 to below 60, and 6.25 mg daily for CrCl below 30 or for hemodialysis. The saxagliptin label specifies 2.5 mg daily when eGFR is below 45 mL/min/1.73 m² or during hemodialysis, with dosing after hemodialysis; strong CYP3A4/5 inhibitors also limit saxagliptin to 2.5 mg daily. Note that alogliptin uses creatinine clearance and saxagliptin uses eGFR for these labeled cutoffs. Linagliptin generally requires no renal dose adjustment. Reassess kidney function, interactions, prior pancreatitis, and the need for modest glucose-lowering efficacy; do not combine a DPP-4 inhibitor with a GLP-1 receptor agonist or dual GIP/GLP-1 therapy (Alogliptin tablets, 2025; Saxagliptin tablets, 2025; American Diabetes Association Professional Practice Committee for Diabetes, 2026c).

A patient with eGFR 24 mL/min/1.73 m² receiving a full standard sitagliptin dose needs a medication-dose review. The answer is not automatically to stop all DPP-4 therapy; confirm the agent, kidney function trend, other drugs, and whether its modest additional glucose lowering remains worthwhile. Avoid concurrent DPP-4 inhibitor and GLP-1 receptor agonist therapy because their overlapping incretin mechanisms generally do not provide a useful complementary benefit.

Clinical role and limitations

These medications should not be presented as equivalent to GLP-1 receptor agonists in weight reduction or cardiovascular outcomes. Avoid combining a DPP-4 inhibitor with a GLP-1 receptor agonist because the mechanisms overlap with little additive benefit. Review drug-specific warnings, including heart failure hospitalization concerns reported with some agents, when selecting treatment for a patient with established HF.

GLP-1 receptor agonists

Avoid unnecessary treatment combinations and reduce hypoglycemia risk

Before adding a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist, review existing insulin, sulfonylurea, and meglitinide doses. The 2026 ADA standards recommend reassessing these higher-hypoglycemia-risk drugs when introducing or escalating treatment. Concurrent DPP-4 inhibitor treatment with GLP-1-based therapy is not recommended because it adds no meaningful glucose-lowering benefit. For type 2 diabetes without severe hyperglycemia or metabolic crisis, GLP-1-based therapy is generally preferred before insulin initiation, subject to the patient’s clinical presentation and contraindications (American Diabetes Association Professional Practice Committee for Diabetes, 2026c).

GLP-1 receptor agonists emulate incretin signaling, enhancing glucose-dependent insulin secretion, reducing inappropriate glucagon signaling, and slowing gastric emptying in a product-dependent manner. They can improve satiety and support weight reduction, but tolerability, access, concomitant drugs, and clinical outcome evidence influence selection.

Nausea and other gastrointestinal symptoms can undermine persistence. Review the selected incretin drug, oral or injection instructions, dose escalation, food effects, and missed-dose guidance rather than generalizing across formulations. Before anesthesia or deep sedation, coordinate a procedure-specific plan because delayed gastric emptying may increase residual gastric contents. The 2026 ADA guidance favors individualized assessment of gastrointestinal symptoms, dose escalation, indication, and procedure risk; it does not prescribe an automatic one-week hold for every weekly GLP-1 or dual GIP/GLP-1 agent. If the drug is held, establish an alternative plan when glycemic deterioration is expected (American Diabetes Association Professional Practice Committee for Diabetes, 2026b; Sease & Blake, 2026).

Agent-level initiation and the dual-incretin distinction

GLP-1 receptor agonists increase glucose-dependent insulin release, suppress inappropriate glucagon secretion, slow gastric emptying, and increase satiety. Agents differ by administration route, dosing frequency, dose-escalation schedule, glycemic efficacy, weight effect, and evidence for cardiovascular outcomes. A practical example is injectable semaglutide, which commonly starts at 0.25 mg once weekly for tolerability rather than immediate full glycemic efficacy; treatment is advanced at scheduled intervals if tolerated. Product-specific instructions determine the actual dose sequence (Sease & Blake, 2026).

Tirzepatide activates GIP and GLP-1 receptors and is pharmacologically distinct from DPP-4 inhibitors and single-receptor GLP-1 agonists. In type 2 diabetes with metabolic dysfunction-associated steatotic liver disease, the 2026 ADA standards support considering a GLP-1 receptor agonist with demonstrated benefit in MASH or a dual GIP/GLP-1 agonist with potential MASH benefit. These evidence grades differ and do not imply that every agent, dose, or marketed indication provides equivalent liver outcomes (American Diabetes Association Professional Practice Committee for Diabetes, 2026c).

Prescribing distinction: a DPP-4 inhibitor and a GLP-1 receptor agonist act on the same incretin pathway at different points; combining them generally adds limited therapeutic value and should prompt medication reconciliation rather than routine dual use. When adding a GLP-1-based agent to insulin or a sulfonylurea regimen, explicitly review hypoglycemia risk and whether doses of the existing agents need adjustment. Reassessment should document glucose response, intake, weight trend, tolerability, and the actual reason the medication was selected (Sease & Blake, 2026).

Before prescribing, review prior pancreatitis, gallbladder symptoms, substantial gastrointestinal disease, relevant personal or family endocrine tumor history, pregnancy intentions, affordability, and ability to follow the titration schedule. Escalation during persistent vomiting or dehydration can cause avoidable harm. If insulin or sulfonylureas are also prescribed, assess the need to adjust those doses as glucose improves.

What limits a pharmacologically attractive choice

Incretin agonism can improve glucose control and promote satiety, but persistent nausea, vomiting, severe GI symptoms, medication cost, administration requirements, and the ability to follow titration can determine whether the treatment is sustainable. GLP-1 receptor agonists vary by drug, formulation and dosing interval; a single exenatide regimen must not be generalized across the class.

Combination decisions

Before adding another incretin-related treatment, compare mechanisms and anticipated incremental value. A DPP-4 inhibitor works through endogenous incretin preservation, whereas GLP-1 receptor agonists directly stimulate the pathway. Combining therapies with overlapping mechanisms should not be assumed to yield proportional benefit; treatment selection should identify an explicit rationale for each agent.

Treatment changes when glycemia, weight, and tolerability compete

Before dose escalation, confirm the exact agent, route, prior dose, time since the last increase, and whether nausea, emesis, or poor intake persists. A higher labeled dose is not automatically the best dose if the patient has lost the ability to tolerate regular meals or hydration. Assess concurrent sulfonylurea or insulin therapy, because hypoglycemia risk may increase through the combination despite glucose-dependent incretin activity. Counsel on dose-specific missed-injection instructions rather than applying one brand’s rules to all formulations (Sease & Blake, 2026).

Prescribing when metabolic liver disease is part of the phenotype

In type 2 diabetes with obesity and suspected metabolic dysfunction-associated steatotic liver disease (MASLD), a medication review should consider weight, liver-related risk, established cardiovascular or kidney disease, tolerability, and product indication together. Contemporary pharmacotherapy discussions highlight selected GLP-1-based and dual GIP/GLP-1-based approaches in patients with metabolic liver disease. This does not establish that every agent or dose in either class produces the same liver outcomes (Sease & Blake, 2026).

Escalation should remain contingent on treatment tolerance, adequate hydration and nutrition, and the patient’s ability to obtain subsequent doses. If persistent vomiting or poor intake develops, evaluate dehydration and other clinically significant complications instead of escalating automatically. A documented plan should say which symptom prompts contact, which medication should be held or reconsidered, and when reassessment is expected.

SGLT2 inhibitors

SGLT2 inhibitors decrease renal glucose reabsorption, increasing urinary glucose excretion. Evidence for kidney and cardiovascular outcomes has increased the importance of this class in patient selection. However, glucose-lowering effect and cardiorenal indication are separate decisions: drug selection should be based on the patient’s conditions and the individual agent’s current eligibility.

Screen for dehydration, genitourinary symptoms, relevant kidney measures, diuretic exposure, and illness-related interruption needs. Counsel about genital yeast infections and symptoms requiring urgent assessment. Renal eligibility, perioperative interruption, ketoacidosis precautions and product-specific counseling require particular attention when prescribing.

In a 2022 network meta-analysis including nine trials and 81,206 participants, Kawai and colleagues found lower composite renal-event risk with SGLT2 inhibitors than with GLP-1 receptor agonists in indirect comparisons across albuminuria strata. They did not find a significant between-class difference in major adverse cardiovascular events. Because the comparisons were indirect, outcome definitions varied, and drug trials were pooled, these findings are not a blanket rule favoring every SGLT2 drug for every patient (Kawai et al., 2022).

Kidney and heart outcomes, plus preventable complications

SGLT2 inhibitors reduce renal glucose reabsorption and induce glucosuria, with benefits that may extend beyond glucose lowering. Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin differ in their specific outcome evidence and approved indications; do not generalize all cardiovascular, kidney, and heart failure indications to every product. The expected A1c response becomes smaller as eGFR falls, but cardiorenal benefits may remain relevant at lower kidney function, depending on the agent and indication.

Empagliflozin provides an example of tablet initiation commonly at 10 mg orally each morning, with later selection based on the treated indication, glucose response, eGFR, tolerability, and product labeling. A patient with dehydration and orthostatic symptoms should be evaluated before starting or escalating therapy. Do not use the same renal threshold for glucose-lowering effectiveness and cardiorenal indication without checking the actual product (Sease & Blake, 2026).

Counsel patients taking SGLT2 inhibitors about genital mycotic symptoms, volume depletion, hypotension, and ketoacidosis even without marked hyperglycemia. Risk increases with prolonged fasting, serious acute illness, surgery, marked carbohydrate restriction, and abrupt insulin reduction. For elective surgery, stop canagliflozin, dapagliflozin, and empagliflozin at least 3 days beforehand and ertugliflozin at least 4 days beforehand. Do not restart solely because the scheduled procedure has ended: reassess oral intake, clinical stability, hydration, and unresolved ketoacidosis risk. For patients hospitalized with heart failure, the 2026 ADA guidance permits initiation or continuation only after recovery from acute illness and when contraindications are absent. Persistent nausea, abdominal pain, dyspnea, vomiting, or unexplained malaise warrants prompt evaluation for possible ketoacidosis regardless of glucose level (American Diabetes Association Professional Practice Committee for Diabetes, 2026b; Sease & Blake, 2026).

In a patient with CKD or heart failure, evaluate eGFR, blood pressure, extracellular volume, diuretics, and relevant medication labeling before initiation. Explain why organ protection may remain a goal even when the A1c is near the individualized target.

Cardiorenal reasoning

Canagliflozin and dapagliflozin reduce renal glucose reabsorption. Kidney-related outcomes may matter independently of changes in A1c. In the 2022 network meta-analysis, SGLT2 inhibitors were associated with lower composite renal risk than GLP-1 receptor agonists in the populations analyzed, while a statistically significant difference in major adverse cardiovascular events was not shown between the classes. This was indirect comparative evidence, not proof that every individual agent is superior.

Preventable harms

Review fluid status, blood pressure, genitourinary symptoms, and acute illness plans before and during treatment. Genital fungal infections and volume depletion can interrupt therapy. Patients also need to understand that serious illness may require reassessment even when glucose measurements are not markedly elevated. Kidney eligibility and temporary-interruption instructions are product- and indication-specific; a generic class description cannot replace them.

Assess the reason for prescribing before interpreting the A1c

SGLT2 glucose-lowering effectiveness decreases as kidney function declines, but eligible patients may still gain kidney and heart failure benefit independent of A1c. The ADA 2026 CKD recommendation supports starting an SGLT2 inhibitor with demonstrated renal benefit in adults with T2DM and CKD at eGFR at least 20 mL/min/1.73 m². This is a class-level clinical recommendation, not a blanket statement that all SGLT2 products share every indication. For empagliflozin, current labeling does not recommend use solely for glycemic control when eGFR is below 30 mL/min/1.73 m²; its organ-protective indication must be assessed separately. Review volume status, ketosis risk, illness-related interruptions and the specific product label before prescribing (American Diabetes Association Professional Practice Committee for Diabetes, 2026a; Boehringer Ingelheim Pharmaceuticals, Inc., 2026).

Less frequently used glucose-lowering therapies

Most type 2 diabetes treatment plans use the major drug classes described above. Pramlintide, quick-release bromocriptine, and colesevelam have more limited roles because their incremental glycemic effect, adverse effects, interactions, or treatment burden may outweigh the benefit. They should not be substituted for therapies selected to reduce heart failure or kidney risk (Sease & Blake, 2026).

Pramlintide: an injectable amylin analog

Pramlintide (SymlinPen) is a premeal injectable amylin analog for selected patients with type 1 or type 2 diabetes who already use mealtime insulin. The prescribing label specifies 15 mcg before major meals initially in type 1 diabetes and 60 mcg in type 2 diabetes, with dose escalation no more frequently than every three days as tolerated. Reduce mealtime insulin (including premixed insulin) by 50% at initiation, monitor glucose closely and reassess subsequent insulin doses. Severe hypoglycemia is a boxed warning; confirmed gastroparesis and hypoglycemia unawareness are contraindications. Administer as a separate injection from insulin. When rapid absorption of an oral drug matters, give that drug at least one hour before or two hours after pramlintide; delayed gastric emptying is clinically relevant (AstraZeneca Pharmaceuticals LP, 2019; Sease & Blake, 2026).

Quick-release bromocriptine for type 2 diabetes

Quick-release bromocriptine (Cycloset) is a distinct formulation used for glycemic management in adults with type 2 diabetes. Start 0.8 mg orally with food within two hours of awakening, increase by 0.8 mg no more often than weekly as tolerated, and do not exceed 4.8 mg once daily. If a morning dose is missed, resume the usual dose the next morning rather than doubling it. Orthostatic hypotension, syncope, nausea, and pill burden limit use. With a moderate CYP3A4 inhibitor, do not exceed 1.6 mg daily; avoid concomitant strong CYP3A4 inhibitors. The U.S. label does not establish efficacy in combination with insulin and excludes treatment of type 1 diabetes and DKA. The diabetes formulation and dosing are not interchangeable with bromocriptine regimens for prolactin disorders (Cycloset, 2026; Sease & Blake, 2026).

Colesevelam: modest glucose lowering with substantial interaction potential

Colesevelam may provide modest additional glucose lowering but adds constipation, pill burden, and important drug-binding interactions. An oral dosing option is 1.875 g twice daily or 3.75 g once daily. Check fasting triglycerides before treatment and periodically: colesevelam is contraindicated when triglycerides exceed 500 mg/dL or in patients with a history of hypertriglyceridemia-induced pancreatitis; patients with triglycerides above 300 mg/dL require closer consideration and monitoring. Give interacting medications, including levothyroxine, at least four hours before colesevelam. The label also notes increased exposure to extended-release metformin, so monitor glycemic response if both are prescribed (Colesevelam hydrochloride tablets, 2026).

Clinical decision: medication reconciliation before a niche add-on

A patient taking levothyroxine with stable thyroid tests starts colesevelam and later develops an elevated TSH. Before increasing levothyroxine, confirm the administration schedule and separate the interacting doses. A glucose-lowering choice has created a thyroid-exposure problem; changing the thyroid dose without investigating the interaction may perpetuate unnecessary dose escalation (Colesevelam hydrochloride tablets, 2026; Katz, 2026; Sease & Blake, 2026).

Choose and reassess therapy systematically

Medication reconciliation during intensification

Adding a GLP-1 receptor agonist or dual GIP/GLP-1 agent to a regimen that includes a sulfonylurea or insulin warrants an explicit hypoglycemia review. Assess recent low readings, meal regularity, and the contribution of each current agent before changing the regimen. A medication that improves A1c but increases treatment burden or recurrent hypoglycemia may not improve overall therapeutic value. The follow-up plan should distinguish expected gastrointestinal effects from persistent inability to maintain hydration or nutrition.

For a patient starting an SGLT2 inhibitor, review genital infection symptoms, orthostatic symptoms, volume status, kidney function, fasting practices, and the conditions that require temporary interruption. Hold these drugs during circumstances associated with increased ketoacidosis risk, including prolonged fasting with acute illness or surgery. Explain that ketoacidosis can occur without extreme hyperglycemia and that vomiting, abdominal pain, or rapid breathing requires urgent assessment.

Long-term metformin therapy also requires monitoring beyond A1c. If fatigue, anemia, or worsening neuropathic symptoms develop, review vitamin B12 status and medication exposure; periodic B12 assessment is recommended. The medication plan should document the indication, target outcome, anticipated adverse effects, and an explicit stop or reassessment condition. (Sease & Blake, 2026).

Dominant concern	Clinical interpretation	Prescribing implications
Irregular meals or prior hypoglycemia	Secretagogue exposure may not match food	Prefer a plan with manageable hypoglycemia risk; review low-glucose education.
Heart failure or fluid retention	A1c alone will miss clinical deterioration	Avoid ignoring TZD-associated edema; review suitability of other classes.
Albuminuria or reduced eGFR	Kidney risk can drive selection independent of A1c	Evaluate albuminuria/eGFR and agent-specific evidence before choosing.
Obesity or treatment burden	Weight effects and dosing frequency influence persistence	Consider efficacy, tolerability, route, access, and patient preference.
Persistent adverse effects	The drug may be unsuitable even if A1c improves	Modify formulation, dose or class according to validated prescribing guidance.

A clinical choice must reach an outcome

For each patient, record the principal problem, the competing benefit and harm, the selected or reconsidered class, what the patient can realistically take, and what finding would make the plan change. For example, a patient with inconsistent eating and recurrent lows on glyburide needs a reassessment of hypoglycemia-producing therapy, not simply another drug added because A1c is above goal. A patient with albuminuria and near-target A1c requires evaluation of kidney risk independent of the glucose result.

Document a class-specific exit strategy at the time of prescribing

An effective initial prescription also states the circumstances that should prompt dose reduction, interruption, or replacement. For a sulfonylurea, recurrent hypoglycemia or unreliable meal access should trigger reconsideration of the secretagogue. For a TZD, new edema or clinical heart failure requires immediate assessment of drug-related fluid retention. For an SGLT2 inhibitor, reduced intake, dehydration, vomiting, or a planned major procedure calls for an individualized interruption plan with explicit restart criteria. For a GLP-1 receptor agonist or tirzepatide, poor fluid or nutrition intake during severe gastrointestinal intolerance may outweigh the value of further dose escalation (Sease & Blake, 2026).

These exit decisions are not synonymous with therapeutic failure. A medication may be effective against A1c yet unsuitable for the patient’s physiology, treatment burden, or safety profile.

Applied prescribing decisions

Case: Missed meals with recurrent symptomatic lows

A patient taking glipizide intermittently skips lunch and has midafternoon hypoglycemia. Review actual administration and food timing, quantify low-glucose events, and reassess whether an insulin secretagogue is an acceptable strategy. A lower A1c is not evidence of successful treatment when it is accompanied by recurrent hypoglycemia.

Case: Albuminuria despite improved glucose

A patient’s A1c has improved, but albuminuria persists. The decision should include kidney risk reduction rather than another glucose-target adjustment alone. Review the complete renal and cardiovascular profile, current therapy, kidney function, and eligibility for organ-protective medications.

Case: Worsening edema after improved glycemia

A patient reports weight gain, ankle edema, and exertional dyspnea after starting a TZD. Investigate possible drug-related volume retention promptly and reassess therapy rather than continuing solely because glucose measurements improved.

Counseling that changes medication safety

Teach patients taking an SGLT2 inhibitor to recognize dehydration and possible ketoacidosis during acute illness, including presentations without extreme hyperglycemia. Patients starting an incretin-based therapy should explain the formulation-specific dosing interval, escalation schedule, gastrointestinal adverse effects, and what to do if oral intake or hydration becomes inadequate. When acarbose is combined with insulin or a secretagogue, explain that symptomatic hypoglycemia in an awake patient who can swallow requires glucose (dextrose), not sucrose-containing candy, because acarbose delays sucrose breakdown. Teach the indicated emergency response for severe hypoglycemia and verify rescue supplies and understanding (Acarbose tablets, 2026; Sease & Blake, 2026).

High-yield distinctions

Select noninsulin agents by the patient’s comorbidities and safety constraints, not by A1c alone. Secretagogues increase hypoglycemia risk, while several other classes have organ-specific benefits and prescribing limitations.

Related YourDNP Resources

Pharmacology hub · Diabetes mellitus · Individualizing type 2 diabetes treatment · Insulin therapy · Diabetic kidney disease · Diabetes monitoring

---

---

References

Acarbose tablets [Prescribing information]. (2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=29939129-7d09-4c22-bf3e-491a8a97f4c4

Alogliptin tablets [Prescribing information]. (2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b25f155a-1259-47c2-aa3b-7c1356e4c7f6

American Diabetes Association Professional Practice Committee for Diabetes. (2026a). 11. Chronic kidney disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care, 49(Supplement 1), S246–S260. https://doi.org/10.2337/dc26-S011

American Diabetes Association Professional Practice Committee for Diabetes. (2026b). 16. Diabetes care in the hospital: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S339–S355. https://doi.org/10.2337/dc26-S016

American Diabetes Association Professional Practice Committee for Diabetes. (2026c). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care, 49(Supplement 1), S183–S215. https://doi.org/10.2337/dc26-S009

AstraZeneca Pharmaceuticals LP. (2019). SymlinPen (pramlintide acetate) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4aea30ff-eb0d-45c1-b114-3127966328ff

Boehringer Ingelheim Pharmaceuticals, Inc. (2026). Jardiance (empagliflozin) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565

Colesevelam hydrochloride tablets [Prescribing information]. (2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ffd02a3-86b8-4af7-b539-aa32e38c6b12

Cycloset (bromocriptine mesylate) [Prescribing information]. (2026, January 12). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e42ba916-16b9-4d1c-8d09-9d2fbb1b6c20

Katz, M. D. (2026). Thyroid disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1420–1454). McGraw Hill.

Kawai, Y., Uneda, K., Yamada, T., Kinguchi, S., Kobayashi, K., Azushima, K., Kanaoka, T., Toya, Y., Wakui, H., & Tamura, K. (2022). Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: A systematic review and network meta-analysis. Diabetes Research and Clinical Practice, 183, 109146. https://doi.org/10.1016/j.diabres.2021.109146

Pioglitazone tablets [Prescribing information]. (2023). DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ba52f865-5768-4035-8505-53049e1effd8&type=display

Repaglinide tablets [Prescribing information]. (2025). DailyMed. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ae28683-28cc-408e-90f9-6a3dddfc668d

Saxagliptin tablets [Prescribing information]. (2025). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e286ffd4-c598-47fb-af06-2e15f7e6f99f

Sease, J. M., & Blake, E. W. (2026). Diabetes mellitus. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1372–1419). McGraw Hill.